TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB41933

Peptide_Name

Pep27anal3

Activity

Anticancer

Activity_category_statistics

Cancer-related peptides

Database_Source

ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 Peptipedia SATPdb dbACP iACP-DRLF

Sequence_Type

standard

Has_Modification No

Description A 27-aa standard natural anticancer peptide sequence curated from ACP740 _ACP240, AntiCP 2.0, CancerPPD 2.0, and other sources, with an available 3D structural model.

Sequence

MRKWFHNVLSSGQLLADKWPAWDYNRK

FASTA

>TPDB41933|Anticancer|length=27
MRKWFHNVLSSGQLLADKWPAWDYNRK

Formula C155H228N44O38S1

Absent Amino Acids CEIT

Common Amino Acids LKW

Mass 3347.85

PI 10.45

Basic Residues 6

Acidic Residues 2

Hydrophobic Residues 12

Net Charge +3

Boman Index 0.35

Hydrophobicity -0.930

Aliphatic Index 61.48

Half Life

Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour

Extinction Coefficient Cystines 17990

Absorbance 280nm 537.36

Polar Residues 6

number

2

A

2

R

2

N

2

D

0

C

0

E

1

Q

1

G

1

H

0

I

3

L

3

K

1

M

1

F

1

P

2

S

0

T

3

W

1

Y

1

V

Amino Acid Distribution

A: 2 R: 2 N: 2 D: 2 C: 0 E: 0 Q: 1 G: 1 H: 1 I: 0 L: 3 K: 3 M: 1 F: 1 P: 1 S: 2 T: 0 W: 3 Y: 1 V: 1

Length

27

Formula

C155H228N44O38S1

Mass

3347.85

PI

10.45

Net Charge

+3

Boman Index

0.35

Hydrophobicity

-0.930

C_terminal_Modification

Free

Chirality

L

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Anticancer

Origin

S. pneumoniae

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50= 67 µM

Detail Source Activity Anticancer

Activity Measurement 67 µM

Target

Cancer Type Leukemia Cancer

Cell Line AML-2

Tissue Affected Blood

Assay & Model

Assay MTT/MTS assay

Testing Time 20.08-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2005

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50= 52 µM

Detail Source Activity Anticancer

Activity Measurement 52 µM

Target

Cancer Type Leukemia Cancer

Cell Line HL-60

Tissue Affected Blood

Assay & Model

Assay MTT/MTS assay

Testing Time 20.08-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2005

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50= 50 µM

Detail Source Activity Anticancer

Activity Measurement 50 µM

Target

Cancer Type Blood Cancer

Cell Line Jurkat

Tissue Affected Blood

Assay & Model

Assay MTT/MTS assay

Testing Time 20.08-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2005

Evidence 4 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50= 50 µM

Detail Source Activity Anticancer

Activity Measurement 50 µM

Target

Cancer Type Gastric Cancer

Cell Line SNU-601

Tissue Affected Stomach

Assay & Model

Assay MTT/MTS assay

Testing Time 20.08-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2005

Evidence 5 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50= 38 µM

Detail Source Activity Anticancer

Activity Measurement 38 µM

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 20.08-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2005